EMA and US FDA to accept single orphan drug designation annual report
This article was originally published in Scrip
Sponsors of orphan drugs and biologics now have the option of submitting a single annual report to the European Medicines Agency and the US Food and Drug Administration for products designated in both jurisdictions.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.